The Lancet Commission on prostate cancer highlights the projected surge in prostate cancer cases worldwide, with the number of new cases expected to rise from 1.4 million in 2020 to 2.9 million by 2040. This increase is driven by demographic changes and rising life expectancy, particularly in low- and middle-income countries (LMICs). The surge cannot be prevented by lifestyle changes or public health interventions alone, and governments must prepare strategies to address it. The Commission recommends early diagnosis, improved diagnostic pathways, and better access to treatment, especially in LMICs. Late diagnosis is widespread, particularly in LMICs, and early diagnosis improves outcomes. The Commission also emphasizes the need for better access to radiotherapy and surgery, as well as the use of artificial intelligence to aid diagnosis and treatment. Research into ethnic differences in prostate cancer prevalence and the development of risk-stratified regulatory models are also highlighted. The Commission calls for urgent action to improve prostate cancer care globally, including education and outreach programs to increase awareness. The findings underscore the need for a global strategy to address the rising burden of prostate cancer, with a focus on early detection, improved treatment, and better access to care. The Commission also highlights the importance of research into the genetic and environmental factors contributing to prostate cancer disparities. The findings provide a roadmap for healthcare providers, policymakers, and researchers to address the growing global burden of prostate cancer.The Lancet Commission on prostate cancer highlights the projected surge in prostate cancer cases worldwide, with the number of new cases expected to rise from 1.4 million in 2020 to 2.9 million by 2040. This increase is driven by demographic changes and rising life expectancy, particularly in low- and middle-income countries (LMICs). The surge cannot be prevented by lifestyle changes or public health interventions alone, and governments must prepare strategies to address it. The Commission recommends early diagnosis, improved diagnostic pathways, and better access to treatment, especially in LMICs. Late diagnosis is widespread, particularly in LMICs, and early diagnosis improves outcomes. The Commission also emphasizes the need for better access to radiotherapy and surgery, as well as the use of artificial intelligence to aid diagnosis and treatment. Research into ethnic differences in prostate cancer prevalence and the development of risk-stratified regulatory models are also highlighted. The Commission calls for urgent action to improve prostate cancer care globally, including education and outreach programs to increase awareness. The findings underscore the need for a global strategy to address the rising burden of prostate cancer, with a focus on early detection, improved treatment, and better access to care. The Commission also highlights the importance of research into the genetic and environmental factors contributing to prostate cancer disparities. The findings provide a roadmap for healthcare providers, policymakers, and researchers to address the growing global burden of prostate cancer.